← Black Diamond Therapeutics, Inc. (BDTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Black Diamond Therapeutics, Inc. (BDTX)
Biological Products, (No Diagnostic Substances) · market cap $107M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Black Diamond Therapeutics (BDTX) is a micro-cap oncology biotech with 24 employees and ~$109M market cap, focused on its lead asset silevertinib (BDTX-1535) in Phase 2 trials for EGFR-mutant Non-Small Cell Lung Cancer and, in combination with temozolomide, for Glioblastoma. The company holds ~$30.1M in cash, implying roughly 8.8 months of runway, making near-term capital raises a near-certainty absent a partnership or significant data readout.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| silevertinib (BDTX-1535) monotherapy | Phase 2 | Non-Small Cell Lung Cancer |
| silevertinib in combination with temozolomide | Phase 2 | Glioblastoma (GBM) |
Price & technical context
3-month
-3.6%
6-month
-20.5%
12-month
-48.9%
52-wk range
$1.61–$4.87
vs 50-day MA
-4.0%
vs 200-day MA
-16.3%
Realized vol
84.9%
Max drawdown
-79.8%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BDTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.